Uncategorized
Luminate meets primary endpoint in phase 2 study
The phase 2 study evaluating the safety and efficacy of Luminate in patients with vitreomacular traction or vitreomacular adhesion has met its primary endpoint, Allegro Ophthalmics announced in a press release. The prospective, double-masked, placebo-controlled study included 106 patients randomized to receive 2 mg, 2.5 mg or 3.2 mg Luminate (ALG-1001) or a balanced salt solution placebo.